Mirae Asset Global ETFs Holdings
CRSP icon

Mirae Asset Global ETFs Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.48M Buy
94,716
+5,008
+6% +$264K 0.01% 851
2025
Q4 		$4.71M Sell
89,708
-9,496
-10% -$569K 0.01% 819
2025
Q3 		$6.42M Sell
99,204
-6,194
-6% -$356K 0.01% 743
2025
Q2 		$5.12M Buy
105,398
+30,065
+40% +$1.16M 0.01% 751
2025
Q1 		$2.58M Sell
75,333
-4,634
-6% -$196K 0.01% 1002
2024
Q4 		$3.14M Buy
79,967
+14,125
+21% +$667K 0.01% 913
2024
Q3 		$3.1M Sell
65,842
-11,176
-15% -$567K 0.01% 930
2024
Q2 		$4.17M Buy
+77,018
New +$4.45M 0.01% 806

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return